What are the functions and efficacy of Alfa deoxyribonuclease inhaler (Pulmozyme)?

(Pulmozyme) is an important advance in the treatment of cystic fibrosis (CF) and the first new drug to treat this disease in 30 years. This product is an enzyme product isolated and extracted from mammalian pancreas or hemolytic streptococcus culture medium. It was developed with the advancement of biotechnology. Now it is mostly a recombinant form of natural human deoxyribonuclease (also known as DNase or recombinant human DNase). It contains 260 amino acids and is exactly the same in sequence as natural human DNase. So, what are the functions and effects of Pulmozyme?

What does Pulmozyme do?

PULMOZYME is recombinant human deoxyribonuclease I (rhdnase), an enzyme that selectively cuts DNA. In preclinical in vitro studies, PULMOZYME hydrolyzed DNA in sputum from CF patients and reduced sputum viscoelasticity. In patients with CF, retention of viscous purulent secretions in the airways can lead to decreased lung function and worsening of infections. Purulent lung secretions contain very high concentrations of extracellular DNA that are released by denatured leukocytes that accumulate in response to infection.

What are the benefits of Pulmozyme?

Dr. Margaret Hodson, Director of the Pulmonary Fibrosis Department at Royal Brompton Hospital in London, said: Although Pulmozyme cannot cure pulmonary fibrosis, it can significantly improve patients' quality of life.

An 18-year-old man suffered from pulmonary fibrosis for 4 years. After taking Pulmozyme for 4 months, his symptoms improved significantly. He was able to participate in sports activities and some physical activities without feeling asthmatic. Dr. Hodson also pointed out that patients who participated in the 6-month Pulmozyme phase and then continued to use Pulmozyme for 6 months had improved lung function, which was related to the continued use of Pulmozyme.

Recommended hot articles: